The researchers propose to develop a Canada-wide, pragmatic, adaptive randomized clinical
platform trial to assess the effectiveness of various interventions in patients with
lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1
of 4 arms, including placebo/standard of care (control) and 3 interventions. Because this is
an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added.
Interventions will last for 2 months and participants will be followed for an additional 4
months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited
across Canada. Results from this trial will accelerate the availability of high-quality,
real-time evidence and solutions to enable Canada to improve the clinical care of patients
with Long COVID.